Switching to a New Weight-Loss Medication From Current GLP-1
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests whether switching from your current GLP-1 medication (like Ozempic or Wegovy) to a new drug called maridebart cafraglutide works as well or better for weight management. You must have already lost at least 10% of your body weight on your current GLP-1 and be doing well with it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking a GLP-1 receptor agonist (a weekly weight-loss or diabetes injection) at a stable dose
- You have lost at least 10% of your body weight on your current GLP-1 medication
- Your weight has been stable for a period of time
- Your stomach and digestion side effects from GLP-1 are stable and manageable
- You have a BMI of 25 or higher (overweight or obese category)
- You do not have Type 1 or Type 2 diabetes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.
This trial tests a new medication (maridebart cafraglutide) to see if it can reduce fat in the liver and help with weight loss. It may be an option for adults with excess liver fat and obesity or overweight who haven't been able to lose weight with diet and exercise alone.
This study tests a new weight-loss medication called maridebart cafraglutide against a placebo in people with moderate to severe obstructive sleep apnea who are not using a CPAP machine. The goal is to find out if weight loss can reduce symptoms like pauses in breathing during sleep.
Hear when a new Obesity or Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.